文献速递肝病消化道肿瘤与早癌

肝细胞癌患者接受ABO血型不合成人活体供肝移植的结局

Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2018-02-13

该回顾性研究纳入韩国单中心2008年11月至2015年12月因肝细胞癌行活体供肝移植的患者,ABO血型不合组165例、ABO血型相容组753例,经1:1倾向评分匹配后每组各165例。ABO血型不合组接受血浆置换和利妥昔单抗(300-375 mg/m2体表面积)脱敏。两组无复发生存率(HR 1.14;95% CI 0.68-1.90;p=0.630)和总生存率(HR 1.10;95% CI 0.60-2.00;p=0.763)相当。

要点

  • 匹配后ABO血型不合组与相容组无复发生存率相当(HR 1.14;95% CI 0.68-1.90;p=0.630)。
  • 匹配后两组总生存率相当(HR 1.10;95% CI 0.60-2.00;p=0.763)。
  • 作者认为ABO血型不合活体供肝移植是肝细胞癌患者的可行选择,尤其适用于符合传统米兰标准且肝硬化代偿者。

核心结论

  • 作者认为ABO血型不合肝移植是肝细胞癌患者的可行选择,尤其适用于符合传统米兰标准且肝硬化代偿者。
  • 尽管脱敏方案可能影响肝细胞癌复发的免疫学担忧存在,但本研究经验显示ABO血型不合与相容活体供肝移植的长期总生存率和无复发生存率无显著差异。

研究设计与样本

  • 回顾性研究,复习韩国单中心2008年11月至2015年12月因肝细胞癌行活体供肝移植患者的病历。
  • 共165例接受ABO血型不合活体供肝移植、753例接受ABO血型相容活体供肝移植。
  • ABO血型不合受者接受脱敏治疗以克服ABO血型屏障,包括移植前血浆置换和利妥昔单抗(300-375 mg/m2体表面积)给药。
  • 采用1:1倾向评分匹配,每组各纳入165例。

主要发现

  • ABO血型不合组82.4%、ABO血型相容组83.0%的患者肝细胞癌符合传统米兰标准。
  • ABO血型不合组92.1%、ABO血型相容组92.7%的患者Child-Pugh评分为A或B。
  • ABO血型不合组和ABO血型相容组随访时间分别为48.0个月和48.7个月。
  • 两组无复发生存率相当(HR 1.14;95% CI 0.68-1.90;p=0.630)。
  • 两组总生存结局相当(HR 1.10;95% CI 0.60-2.00;p=0.763)。

关键数值与推荐

  • ABO血型不合受者脱敏方案包括移植前血浆置换和利妥昔单抗300-375 mg/m2体表面积。
  • 匹配后ABO血型不合组与相容组无复发生存率HR 1.14(95% CI 0.68-1.90;p=0.630)。
  • 匹配后ABO血型不合组与相容组总生存率HR 1.10(95% CI 0.60-2.00;p=0.763)。

临床怎么用

  • 作者认为ABO血型不合活体供肝移植是肝细胞癌患者的可行选择,尤其适用于符合传统米兰标准且肝硬化代偿者。
  • 本研究中心的做法是ABO血型不合受者接受包括移植前血浆置换和利妥昔单抗(300-375 mg/m2体表面积)的脱敏治疗。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Living-donor liver transplantation (LDLT) can simultaneously cure hepatocellular carcinoma (HCC) and underlying liver cirrhosis, improving long-term results in patients with HCC. ABO-incompatible LDLT could expand the living-donor pool, reduce waiting times for deceased-donor liver transplantation, and improve long-term survival for some patients with HCC. METHODS: We retrospectively reviewed the medical records of patients undergoing LDLT for HCC from November 2008 to December 2015 at a single institution in Korea. In total, 165 patients underwent ABO-incompatible and 753 patients underwent ABO-compatible LDLT for HCC. ABO-incompatible recipients underwent desensitization to overcome the ABO blood group barrier, including pretransplant plasma exchange and rituximab administration (300-375 mg/m2 /body surface area). RESULTS: We performed 1:1 propensity score matching and included 165 patients in each group. 82.4% of ABO-incompatible and 83.0% of -compatible LDLT groups had HCC within conventional Milan criteria, respectively, and 92.1% and 92.7% of patients in each group had a Child-Pugh score of A or B. ABO-incompatible and -compatible LDLT groups were followed up for 48.0 and 48.7 months, respectively, with both groups showing comparable recurrence-free survival rates (hazard ratio [HR] 1.14; 95% CI 0.68-1.90; p = 0.630) and overall patient-survival outcomes (HR 1.10; 95% CI 0.60-2.00; p = 0.763). CONCLUSIONS: These findings suggested that ABO-incompatible liver transplantation is a feasible option for patients with HCC, especially for those with compensated cirrhosis with HCC within conventional Milan criteria. LAY SUMMARY: Despite hypothetical immunological concerns that the desensitization protocol for breaking through the ABO blood group barrier might have a negative impact on the recurrence of hepatocellular carcinoma, our experience demonstrated no significant differences in the long-term overall survival and recurrence-free survival rates between patients receiving ABO-compatible or ABO-incompatible liver transplantation. In conclusion, results from our institution indicated that ABO-incompatible living-donor liver transplantation constitutes a potentially feasible option for patients with hepatocellular carcinoma, especially those with compensated cirrhosis with hepatocellular carcinoma within conventional Milan criteria.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Yoon YI, Song GW, Lee SG, et al. Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma. J Hepatol. 2018. PMID: 29452208. doi:10.1016/j.jhep.2018.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。